The Food and Drug Administration has expanded the warning label on a group of prostate drugs, saying they may increase the risk of a serious form of prostate cancer. The FDA is updating the warning information on a group of drugs including GlaxoSmithKline’s Avodart and Merck’s Proscar, which are used to shrink the prostate. The warning indicates the drugs are linked to a greater risk of high-grade prostate cancers. While the drugs have been shown to reduce the risk of prostate cancer overall, according to the FDA, the drugs were linked to an increased risk of more serious cancers.
Earlier this year, Merck and GlaxoSmithKline asked the FDA to approve the drugs as preventive treatments for prostate cancer, but the agency refused, citing the risk of high-grade cancer. In March, GlaxoSmithKline said it was abandoning global efforts to get Avodart approved as a preventive cancer drug. The agency is basing its conclusions on a review of two studies in which about 27,000 men age 50 and older used the drugs for several years. The FDA said the risk of high-grade prostate cancers is small, but doctors should be aware of it. The drugs are also known as dutasteride and finasteride, respectively. Finasteride is also available as a low-cost generic.
Source: USA Today
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.